The IMpassion130 trial was a global, randomised, double-blind, phase III study of atezolizumab+nab-paclitaxel versus placebo+nab-paclitaxel in patients with treatment naive locally advanced or metastatic triple-negative breast cancer. Here, progression-free survival was statistically significantly longer in patients treated with the combination of atezolizumab+nab-paclitaxel compared with placebo+nab-paclitaxel. The side effect profile was favourable as no unexpected toxicities were observed in the intervention compared with the control arm. In the current podcast, PS provides insight on the response rate and the preliminary survival analysis of IMpassion130. Further possible biomarkers and the impact of the results on the treatment standard in breast cancer are discussed.
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